Data from: Impact of a GABA-producing Lactococcus lactis on microbiota during CNS inflammatory: Part 1
Data files
Mar 02, 2026 version files 2.46 GB
-
16S_rRNA_seqs.zip
2.46 GB
-
Manifest_16S_16S_rRNA.xlsx
19.71 KB
-
README.md
4.37 KB
Abstract
The gut microbial populations are key regulators of immune homeostasis; simultaneously, they are constantly exposed to changes, including those promoted by disease. In experimental autoimmune encephalomyelitis (EAE), the most used animal model to study multiple sclerosis (MS), we and others have documented changes in the abundance of bacterial taxa following the induction of the disease. Some of those changes affect bacteria capable of producing gamma-aminobutyric acid (GABA). Because of the importance of GABA as an inhibitory neurotransmitter and as an immunomodulatory factor that regulates immune cell function and decreases inflammation, we previously genetically engineered a Lactococcus lactis strain to overproduce GABA (P8s-GAD L. lactis). In this work, C57BL/6 Envigo (Env) and Jackson Laboratories (Jax) mice were administered 5 x 108 colony-forming units (CFU) of P8s-GAD L. lactis, unmodified L. lactis (P-L. lactis), or Medium and EAE induction. The administration of P8s-GAD L. lactis was protective in Env mice, while no protective effects were observed in Jax mice. Using Jax mice, we compared the effects of the treatments on EAE, microbiota by 16S rRNA sequencing, and the mycobiota by IST sequencing, in mice treated with the bacterial strains, either with or without glutamic acid, using samples collected at the beginning of the treatment, EAE induction, 14 days after, and at the end of the experiment (day 28). To test whether the bacterial treatments affected the CNS, a whole-brain proteomics analysis was performed in mice at day 28. Despite the lack of protective effects, the treatment with GABA-producing L. lactis (P8s-GAD L. lactis) in EAE resulted in changes to the gut microbiome. Additionally, the proteomics analysis revealed a change in protein profile when mice were treated with P8s-GAD L. lactis. Our study highlights the importance of controlling the source of mice for probiotic and microbiota research in the context of experimental models of immune-mediated diseases.
Dataset DOI: 10.5061/dryad.66t1g1kbv
Description of the data and file structure
This study investigates the Gut-Microbiota-Brain Axis in the context of Multiple Sclerosis (MS) using the Experimental Autoimmune Encephalomyelitis (EAE) model. The primary goal was to evaluate how an engineered, GABA-producing probiotic strain impacts neuroinflammation and whether the host's baseline microbiome influences therapeutic efficacy. The project employed a multi-omic approach to capture the systemic effects of the intervention: 11) Phenotypic: Longitudinal monitoring of EAE clinical scores and body weight; 2) Microbial: Sequencing of both the Microbiota (bacteria) and Mycobiota (fungi) to track dysbiosis and treatment-induced shifts; 3) Proteomic: High-resolution mass spectrometry (Orbitrap Astral) of whole-brain tissue to identify protein-level changes in the CNS resulting from gut-based interventions.
Description of the data and file structure
Files and variables
Variables:
- Timepoints: Stool samples collected at four critical intervals:
- Day -7: Pre-treatment/Acclimation.
- Day 0: EAE Induction.
- Day 14: Acute disease phase.
- Day 28: Endpoint.
- Interventions:
- Orally administered P8s-GAD L. lactis: Engineered GABA-producing strain.
- Orally administered P-L. lactis: Unmodified control strain (plasmid only).
- Control: Sterile bacterial medium.
- Glutamic acid groups: Supplemented with 200 mM glutamic acid.
File: Manifest_16S_16S_rRNA.xlsx
This table represents microbiome sequencing metadata for 16S rRNA gene analysis from mice with active EAE. Each row corresponds to a single stool sample collected at a defined timepoint and includes the paired-end FASTQ files (R1 and R2) used for sequencing analysis. The #SampleID identifies each biological sample (6a–6d), while the TreatmentGroup indicates that all samples are from untreated EAE mice. The metadata columns specify experimental conditions, including glutamic acid status (Glut−) and the collection timepoint relative to EAE induction (−7, 0, 14, and 28 days). The “Description” column confirms these animals had active EAE, and the “Description summary” provides a concise label combining disease status and day of collection. Overall, the table organizes sequencing file names and experimental metadata to enable longitudinal microbiome analysis across disease progression timepoints.
File: 16S_rRNA_seqs.zip
Description: Zipped raw 16S rRNA sequences
1. Overview - 16S rRNA sequencing: This dataset includes longitudinal profiling of the gut microbiome (bacteria) in EAE-induced mice. The analysis tracks shifts in community composition in response to the GABA-producing Lactococcus lactis (P8s-GAD) probiotic across different host backgrounds (Envigo vs. Jackson).
2. Experimental Workflow
- Subject: Mus musculus. Female C57BL/6 mice from Envigo (Env) and Jackson (Jax) laboratories (per group for sequencing)
- Sequencing Methodology:
- Extraction: DNA isolated using Qiagen DNA stool extraction kits.
- Target Regions: 16S rRNA gene, variable regions V3-V4.
- Platform: Illumina MiSeq (v2 chemistry, 2x250bp).
- Library Prep: Nextera XT kit with combined amplification and indexing.
3. Data Acquisition & Bioinformatics
Bioinformatics Pipeline: Data was processed using a cloud-based and open-source workflow:
- Primary Analysis: Nephele (NIAID: https://nephele.niaid.nih.gov/) and QIIME.
- OTU Clustering: Open-reference approach against the SILVA_99 database (99% similarity).
- Quality Control: Chimera identification and removal via uchime.
- Downstream Processing: Handled in RStudio using the phyloseq and vegan packages.
Access information
Microbiome sequencing raw data and metadata files are stored at https://doi.org/10.5061/dryad.66t1g1kbv; Mycobiome sequencing raw data and metadata files are stored at https://doi.org/10.5061/dryad.7d7wm3866. Proteomics raw data and metadata files are stored at https://doi.org/10.5061/dryad.x0k6djj04.
Animals and housing conditions. Ten-week-old female C57BL6 NHsd mice (Envigo RMS, Inc., Indianapolis, IN, USA) (RRID:MGI:2161078) and C57BL6 Jax mice (Jackson Laboratories, Bar Harbor, ME, USA) (RRID:IMSR_JAX:000664) were randomly housed in groups of 5 in wire-top cages with 12-h light/dark cycle (22 ± 1 ºC; 23-33% humidity). All animals weighed approximately 20 grams. Mice had free access to food and water with all care and procedures following Eastern Washington University (EWU) and Boise State University (BSU) institutional policies for animal well-being and health. Teklad 22/5 rodent diet (Envigo RMS) was used in Envigo mice, while Laboratory Rodent Diet 5001 (LabDiet, Inc., Richmond, IN) was used in experiments with Jackson Laboratories mice at BSU. Mice had free access to food and water, were housed and handled ethically with all care and procedures according to an approved Institutional Animal Care and Use Committee (IACUC) for animal well-being and health under IACUC protocols 2018-11-01 (EWU) and AC22-018 (BSU). Whether Env, Jax, or both were used is depicted in Figures 1 and 2 and the corresponding legends. In all EAE experiments, each experimental group consisted of 10 mice (n=10). The sample size for the EAE experiments was selected based on a power analysis performed using previous observed findings by ANOVA on day 25 vs. untreated (p = 0.045 for treatment vs. control) on a desired power of 90% and a significance level of 0.05.
EAE induction and clinical score evaluation. Animals were given one week to acclimate to the housing environments. EAE was induced using an EAE induction kit (Hooke KitTM EK-2110, Hooke Laboratories, Lawrence, MA). The kits use MOG35-55 in emulsion with complete Freund’s adjuvant (CFA) and Pertussis toxin (PTX) in a glycerol buffer. On day 0 of EAE induction, the MOG35-55-CFA emulsion was diluted with PTX in phosphate-buffered saline and injected subcutaneously. PTX toxin injection was repeated the following day (day +1). Mice were scored under blinded observations as described by us and others: 0 – no detectable signs of EAE, 0.5 – distal limp tail, 1.0 – complete limp tail, 1.5 – limp tail and hind limb weakness, 2.0 – unilateral partial hind limb paralysis, 2.5 – bilateral partial hind limb paralysis, 3.0 – complete bilateral hind limb paralysis, 3.5 - complete bilateral hind limb paralysis and partial front limb paralysis, 4.0 – quadriplegia, 5 – dead animal. Attrition: mice that were found dead received a clinical score of 5. Losses not caused by EAE induction were not observed.
Bacterial growth, dosing preparations, and treatments. L. lactis-P8s-GAD and Lactococcus lactis-P (unmodified strain, carrying plasmid without engineered construct) strains were cultured in M17 broth (BD Difco, USA) or agar (Thermo Scientific Chemicals, USA) with 0.5% glucose (Sigma-Aldrich, USA) and 5 mg mL-1 erythromycin (GM17 erm media) at 30 °C without aeration overnight (20). After culture for 18 hr, the strains were diluted to OD600 0.2 in GM17 or GM17 erm and incubated at 30 °C for three hours. At the time of sample collection, the bacterial cell number was determined using a spectrophotometer (OD600). Viable plate count experiments were used previously to correlate cell number with spectrophotometer absorbance at OD600 Mice were treated five times (consecutive)/week with oral gavages with 5 x 108 CFU/mouse of L. lactis strains P-L. lactis (P) or P8s-GAD L. lactis (P8s) suspended in sterile saline. Depending on the experiments, the treatments were done in C57BL/6 mice from Envigo or Jackson Laboratories. Dosing timing varied within studies, and treatments started on the day of EAE induction (Day 0) or seven days before EAE induction (Day minus 7 (Day -7). The treatments continued throughout the experiments until the end (Day 28). The dosing strategies used are depicted in figures and corresponding legends. For some experiments, the GM17 medium used for the bacterial administration was supplemented with 200 mM glutamic acid hydrochloride (Sigma, reference number G2128). One experiment was performed with drinking water supplemented with 200 mM glutamic acid hydrochloride provided to the animals ad libitum.
Stool sample collections and 16S ribosomal RNA (rRNA) and ITS sequencing. Stool samples were collected in sterile tubes on days -7, 0, 14, and 28 post-EAE induction (dpi) and stored at -80°C before use. Seven animals per group (n=7) were used for microbiome and mycobiome stool analysis. Samples were sent to the University of Wyoming for DNA extraction and sequencing. Qiagen DNA stool extraction kits were used for DNA isolation. DNA aliquots (1 ng/ml DNA) were analyzed by PCR using primers specific to the variable regions 3 and 4 (V3-V4) of the prokaryotic 16S rRNA gene and the fungal internal transcribed spacer (ITS) gene. Library preparation and V3-V4 amplicon sequencing were performed on the Illumina MiSeq (RRID: SCR_016379) platform. A modified protocol with Nextera XT kit was used for library preparation, and sequencing was performed using MiSeq V2 (2x250bp) chemistry. The sequencing protocol involved a combined amplification with forward and indexed-reverse primers. After sequencing, the microbiome data were analyzed using Nephele (RRID:SCR_016595), a cloud-based web application from the Office of Cyber Infrastructure and Computational Biology (OCICB), National Institute of Allergy and Infectious Diseases (http://nephele.niaid.nih.gov/; 2016). QIIME (RRID: SCR_008249) was used for analysis (22), and RStudio (RRID:SCR_000432) for statistical analysis (23). Reads that were demultiplexed were clustered into OTUs using an open reference approach by comparison with the SILVA_99 database, allowing sequences to cluster at 99% similarity. Analyses included the identification of chimeras and removal using uchime. The abundance of each taxon was analyzed using the phyloseq package in RStudio. The compositional heterogeneity of each sample's microbial community at every timepoint and each taxonomic level was visualized using PCoA scaling and the ordinate function in the phyloseq package and using the Bray-Curtis dissimilarity index calculated using the metaMDS function in the vegan package.
